| Boehringer Ingelheim (Schweiz) GmbH - Pradif T, Retardtablette |
| 57160 | | 01 | | Pradif T | | Retardtablette | | G04CA02 | | Tamsulosin | | 24.06.2005 | | |
|
| Composition |
| tamsulosini hydrochloridum 400 µg corresp. tamsulosinum 367 µg, macrogolum 8000, magnesii stearas, macrogolum 7'000'000 cum E 321 et silica colloidalis hydrica, Überzug: hypromellosum, macrogolum 8000, E 172 (flavum), pro compresso obducto. |
| Packungsbestandteile |
| Delayed release tablets | | | | | Active Agent | Dose |
|---|
| Tamsulosine Hydrochloride | 400 µg correspond Tamsulosinum 367 µg |
| | BAG: Active Agent | Dose |
|---|
| Tamsulosine Hydrochloride | 400 mcg |
| | | | Inactive agents | Dose | additional_information |
|---|
| (Flavum) | | | | Cum E | 321 | | | E 172 | | color. | | Hypromellosum | | Überzug | | Macrogol | 8000 | | | Magnesii Stearas | | | | Pro Compresso Obducto | | | | Silica Colloidalis Hydrica | | |
| |
|
|
